A retrospective comparative study of 2-drug oral and intramuscular cephalosporin treatment regimens for pharyngeal gonorrhea

Clinical Infectious Diseases

Volumn 56, Issue 11, 2013, Pages 1539-1545

  Barbee, Lindley A ^a   Kerani, Roxanne P ^b   Dombrowski, Julia C ^b   Soge, Olusegun O ^b   Golden, Matthew R ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

antimicrobial resistance; gonorrhea; pharyngeal gonorrhea; sexually transmitted disease; treatment

Indexed keywords

AZITHROMYCIN; CEFIXIME; CEFPODOXIME; CEFTRIAXONE; CEPHALOSPORIN; DOXYCYCLINE; QUINOLONE DERIVATIVE;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; DRUG ADMINISTRATION ROUTE; FEMALE; GONORRHEA; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHARYNX GONORRHEA; PRIORITY JOURNAL; REPEAT PROCEDURE; RETROSPECTIVE STUDY;

ANTIMICROBIAL RESISTANCE; GONORRHEA; PHARYNGEAL GONORRHEA; SEXUALLY TRANSMITTED DISEASE; TREATMENT;

ADMINISTRATION, ORAL; ADULT; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DRUG RESISTANCE, BACTERIAL; FEMALE; GONORRHEA; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MICROBIAL SENSITIVITY TESTS; PHARYNGEAL DISEASES; RETROSPECTIVE STUDIES; RISK; TREATMENT OUTCOME; WASHINGTON;

EID: 84877298072     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit084     Document Type: Article

References (37)

1. Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59(RR-12):1-110.
2. Update to CDC's sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 2012; 61:590-4.
3. Sathia L, Ellis B, Phillip S, Winston A, Smith A. Pharyngeal gonorrhoea-is dual therapy the way forward? Int J STD AIDS 2007; 18:647-8.
4. Moran JS, Levine WC. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis 1995; 20(suppl 1):S47-65.
5. Moran JS. Treating uncomplicated Neisseria gonorrhoeae infections: is the anatomic site of infection important? Sex Transm Dis 1995; 22:39-47.
6. Weinstock H, Workowski KA. Pharyngeal gonorrhea: an important reservoir of infection? Clin Infect Dis 2009; 49:1798-800.
7. Workowski KA, Berman SM, Douglas JM Jr. Emerging antimicrobial resistance in Neisseria gonorrhoeae: urgent need to strengthen prevention strategies. Ann Intern Med 2008; 148:606-13.
8. Whiley DM, Goire N, Lahra MM, et al. The ticking time bomb: escalating antibiotic resistance in Neisseria gonorrhoeae is a public health disaster in waiting. J Antimicrob Chemother 2012; 67:2059-61.
9. Shlaes DM, Gerding DN, John JF Jr, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997; 25:584-99.
10. Wiesner PJ, Tronca E, Bonin P, Pedersen AH, Holmes KK. Clinical spectrum of pharyngeal gonococcal infection. N Engl J Med 1973; 288:181-5.
11. Bro-Jorgensen A, Jensen T. Gonococcal pharyngeal infections: report of 110 cases. Br J Vener Dis 1973; 49:491-9.
12. Tice AW Jr, Rodriguez VL. Pharyngeal gonorrhea. JAMA 1981; 246:2717-9.
13. Ahmed-Jushuf IH, Bradley MG, Rao PM. Oropharyngeal carriage of Neisseria gonorrhoeae and its response to treatment in patients with anogenital infection. Genitourin Med 1988; 64:64-5.
14. Kinghorn G. Pharyngeal gonorrhoea: a silent cause for concern. Sex Transm Infect 2010; 86:413-4.
15. Peters RP, Nijsten N, Mutsaers J, Jansen CL, Morre SA, van Leeuwen AP. Screening of oropharynx and anorectum increases prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae infection in female STD clinic visitors. Sex Transm Dis 2011; 38:783-7.
16. Giannini CM, Kim HK, Mortensen J, Mortensen J, Marsolo K, Huppert J. Culture of non-genital sites increases the detection of gonorrhea in women. J Pediatr Adolesc Gynecol 2010; 23:246-52.
17. Kent CK, Chaw JK, Wong W, et al. Prevalence of rectal, urethral, and pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: San Francisco, California, 2003. Clin Infect Dis 2005; 41:67-74.
18. Stoltey JE, Barry PM. The use of cephalosporins for gonorrhea: an update on the rising problem of resistance. Expert Opin Pharmacother 2012; 13:1411-20.
19. Hutt DM, Judson FN. Epidemiology and treatment of oropharyngeal gonorrhea. Ann Intern Med 1986; 104:655-8.
20. Bernstein KT, Stephens SC, Barry PM, et al. Chlamydia trachomatis and Neisseria gonorrhoeae transmission from the oropharynx to the urethra among men who have sex with men. Clin Infect Dis 2009; 49:1793-7.
21. Bolan GA, Sparling PF, Wasserheit JN. The emerging threat of un-treatable gonococcal infection. N Engl J Med 2012; 366:485-7.
22. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004; 159:702-6.
23. European Committee on Antimicrobial Susceptibility Testing. Clinical breakpoint tables v. 3.0. Available at: http://www.eucast.org/clinical- breakpoints/. Accessed 9 January 2013.
24. Allen VG, Mitterni L, Seah C, et al. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA 2013; 309:163-70.
25. Chisholm SA, Mouton JW, Lewis DA, Nichols T, Ison CA, Livermore DM. Cephalosporin MIC creep among gonococci: time for a pharma-codynamic rethink? J Antimicrob Chemother 2010; 65:2141-8.
26. Lupin Pharmaceuticals. SUPRAX (package insert). Baltimore, MD: Lupin Pharmaceuticals, Inc. Available at: http://www.lupinpharmaceuticals. com/pdf/09/SUPRAX%20Common%20PI%20.pdf. Accessed 20 February 2013.
27. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance, 2010. Atlanta, GA: US Department of Health and Human Services, 2011. Available at: http://www.cdc.gov/std/stats10/default.htm. Accessed 20 February 2013.
28. Waugh MA. Open study of the safety and efficacy of a single oral dose of azithromycin for the treatment of uncomplicated gonorrhoea in men and women. J Antimicrob Chemother 1993; 31(suppl E):193-8.
29. Handsfield HH, Dalu ZA, Martin DH, Douglas JM Jr, McCarty JM, Schlossberg D. Multicenter trial of single-dose azithromycin vs. ceftri-axone in the treatment of uncomplicated gonorrhea. Azithromycin Gonorrhea Study Group. Sex Transm Dis 1994; 21:107-11.
30. Dan M, Poch F, Amitai Z, Gefen D, Shohat T. Pharyngeal gonorrhea in female sex workers: response to a single 2-g dose of azithromycin. Sex Transm Dis 2006; 33:512-5.
31. Furuya R, Nakayama H, Kanayama A, et al. In vitro synergistic effects of double combinations of beta-lactams and azithromycin against clinical isolates of Neisseria gonorrhoeae. J Infect Chemother 2006; 12:172-6.
32. Pereira R, Cole MJ, Ison CA. Combination therapy for gonorrhoea: in vitro synergy testing. J Antimicrob Chemother 2013; 68:640-3.
33. Unemo M, Nicholas RA. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol 2012; 7:1401-22.
34. Jordan WC. Clinical trial of doxycycline in the treatment of anorectal and oropharyngeal gonorrhea. J Natl Med Assoc 1985; 77:1020-1.
35. Lahra MM. Surveillance of antibiotic resistance in Neisseria gonor-rhoeae in the WHO Western Pacific and South East Asian Regions, 2010. Commun Dis Intell 2012; 36:95-100.
36. Van de Laar M, Spiteri G. Increasing trends of gonorrhoea and syphilis and the threat of drug-resistant gonorrhoea in Europe. Euro Sur-veill 2012; 17. pii:20225.
37. Morris SR, Klausner JD, Buchbinder SP, et al. Prevalence and incidence of pharyngeal gonorrhea in a longitudinal sample of men who have sex with men: the EXPLORE study. Clin Infect Dis 2006; 43:1284-9.